TG Therapeutics Inc.

TGTX

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Eventide Asset ManagementNEWFeb 13, 2026

Shares: 716,414Value: $21.4M

# Signal Note: Eventide Initiates TGTX Position Eventide's $21.4M entry into TGTX suggests conviction in the company's hematologic malignancy pipeline, likely driven by near-term catalysts around Ublituximab (anti-CD20 mAb) or Umbralisib (PI3K inhibitor) label expansions or efficacy readouts. The position size (~716k shares) represents material commitment from a values-focused allocator with demonstrated biotech expertise, signaling confidence in clinical data or regulatory pathway clarity. Watch for Phase 2/3 trial readouts in CLL, SLL, or follicular lymphoma over next 12-24 months as key validation points.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CPRT1 fund DECK1 fund LITE1 fund NTAP1 fund GPI1 fund IMMX1 fund PI1 fund UNP1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: